Access and Evidence
Early Access to Medicines Scheme: Lessons from Keytruda
The first product has now gone completely through EAMS: what lessons can other companies learn?
More Access and Evidence Articles
Access and Evidence
The Truth about Pricing
Pharma and payers in South Africa need to change tack to find a middle ground.
Access and Evidence
Harnessing Generic Big Data for Reliable Relevant Insights
Data-driven applications are pointing the way to a new era of modern data management.
Access and Evidence
Making Medicine Accessible to All
Two billion people on the planet do not have access to medicines. How is the pharmaceutical industry trying to change this?
Access and Evidence
Improving Healthcare (and Pharma’s) Performance through Analytics
Leveraging data through analytics can improve healthcare services and health outcomes for patients and communities.
Access and Evidence
The Need for Smart Data
James Weatherall's predictions and why the marriage of data science/analytics and human judgment creates the best decisions.
Access and Evidence
Rules-Based Data Analysis and Predictive Modelling: Stemming the Tide of Non-Adherence
Getting ahead of the problem is key when it comes to tackling non-adherence.
Access and Evidence
Pharma Determined to Change Its Image in South Africa
Pharma's poor image is making it difficult to readily enter into fruitful cooperation with the government.
Access and Evidence
Leveraging Big Data To Crack Open Oncology Insights
Infosys has a framework to evaluate the usage and applicability of Big Data across different segments of the pharma value chain in Oncology.
Access and Evidence
The Science of Cancer Drug Pricing
Calls are being made for new cancer therapies to be priced according to their true value. Danielle Barron investigates.